Maxpro Capital Acquisition Corp.
JMACW
NASDAQ Global Market0.12
USD
+0.02
- -
CIK
0001874259
CUSIP
57778T114
Return %
Stock
S&P500
1Y
-42.88
26.84
3Y
-74.47
77.03
5Y
-74.47
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Hong-Jung Chen
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- No. 89 Songren Road Taipei Taiwan, Province of China 11073
- CIK
- 0001874259
- Similar Companies
- Business
- Maxpro Capital Acquisition Corp. (NASDAQ: JMACW) is a blank check company, or special purpose acquisition company (SPAC), focused on effecting mergers, capital stock exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses. Incorporated in Delaware, the company was formed in 2021 and is headquartered at 5/F-4, No. 89 Songren Road, Xinyi District, Taipei City, Taiwan 11073. It does not have significant current operations and holds cash equivalents primarily from its initial public offering of 9 million units at $10 each in October 2021, raised approximately $90-103.5 million net proceeds deposited in a trust account. Its core offering includes redeemable warrants (JMACW ticker) exercisable at $11.50 per share, alongside its Class A ordinary shares traded under JMAC prior to delisting post-merger. The company targets opportunities globally, particularly in the healthcare sector, as evidenced by its definitive business combination agreement announced in September 2022 with late-stage clinical biopharmaceutical firm Apollomics Inc. valued at approximately $899-910 million pre-money equity. In March 2023, Maxpro's stockholders approved the transaction on March 20, with closing occurring on March 30, 2023; Apollomics became publicly traded on Nasdaq under APLM/APLMW, rendering Maxpro a former entity while its warrants continue trading. No further mergers, acquisitions, funding rounds, or operational shifts have occurred since the Apollomics de-SPAC, with recent mentions tied to post-merger legal resolutions involving Apollomics' Cayman Islands shareholder disputes as of November 2025.